GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (STU:4XC1) » Definitions » EBITDA Margin %

KalVista Pharmaceuticals (STU:4XC1) EBITDA Margin % : 0.00% (As of Jan. 2024)


View and export this data going back to 2016. Start your Free Trial

What is KalVista Pharmaceuticals EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. KalVista Pharmaceuticals's EBITDA for the three months ended in Jan. 2024 was €-30.24 Mil. KalVista Pharmaceuticals's Revenue for the three months ended in Jan. 2024 was €0.00 Mil. Therefore, KalVista Pharmaceuticals's EBITDA margin for the quarter that ended in Jan. 2024 was 0.00%.


KalVista Pharmaceuticals EBITDA Margin % Historical Data

The historical data trend for KalVista Pharmaceuticals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KalVista Pharmaceuticals EBITDA Margin % Chart

KalVista Pharmaceuticals Annual Data
Trend Dec14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -182.56 -315.37 - - -

KalVista Pharmaceuticals Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of KalVista Pharmaceuticals's EBITDA Margin %

For the Biotechnology subindustry, KalVista Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


KalVista Pharmaceuticals's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, KalVista Pharmaceuticals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where KalVista Pharmaceuticals's EBITDA Margin % falls into.



KalVista Pharmaceuticals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

KalVista Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in Apr. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Apr. 2023 )/Revenue (A: Apr. 2023 )
=-100.46/0
= %

KalVista Pharmaceuticals's EBITDA Margin % for the quarter that ended in Jan. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Jan. 2024 )/Revenue (Q: Jan. 2024 )
=-30.243/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


KalVista Pharmaceuticals  (STU:4XC1) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


KalVista Pharmaceuticals EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


KalVista Pharmaceuticals (STU:4XC1) Business Description

Traded in Other Exchanges
Address
55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.

KalVista Pharmaceuticals (STU:4XC1) Headlines

No Headlines